Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer’s Disease Pathophysiology

[1]  W. Jagust,et al.  Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults , 2020, Neurology.

[2]  Jesse A. Brown,et al.  Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.

[3]  M. Bondi,et al.  Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration , 2019, Neurology.

[4]  Lisa Delano-Wood,et al.  Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity , 2019, Brain communications.

[5]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[6]  J. Suckling,et al.  Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study , 2019, Alzheimer's & Dementia.

[7]  R. D'Agostino,et al.  New Guidelines for Statistical Reporting in the Journal. , 2019, The New England journal of medicine.

[8]  David T. Jones,et al.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. , 2019, JAMA.

[9]  C. Jack,et al.  White matter hyperintensities: relationship to amyloid and tau burden. , 2019, Brain : a journal of neurology.

[10]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[11]  Sterling C. Johnson,et al.  ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes , 2019, Neurology.

[12]  David T. Jones,et al.  Entorhinal cortex tau, amyloid-&bgr;, cortical thickness and memory performance in non-demented subjects , 2019, Brain : a journal of neurology.

[13]  D. Y. Lee,et al.  Plasma tau/amyloid-&bgr;1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease , 2019, Brain : a journal of neurology.

[14]  Sterling C. Johnson,et al.  Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age , 2019, Brain : a journal of neurology.

[15]  Keith A. Johnson,et al.  The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals , 2018, Annals of neurology.

[16]  W. Jagust.  Imaging the evolution and pathophysiology of Alzheimer disease , 2018, Nature Reviews Neuroscience.

[17]  Atul Narkhede,et al.  An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease , 2018, Neurology.

[18]  Brian A. Gordon,et al.  Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease , 2018, Neurology.

[19]  L. Ferrucci,et al.  Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults , 2018, Brain : a journal of neurology.

[20]  W. Jagust,et al.  Subthreshold Amyloid Predicts Tau Deposition in Aging , 2018, The Journal of Neuroscience.

[21]  W. Jagust,et al.  Memory decline accompanies subthreshold amyloid accumulation , 2018, Neurology.

[22]  David T. Jones,et al.  Tau-negative amnestic dementia masquerading as Alzheimer disease dementia , 2018, Neurology.

[23]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[24]  Brian A. Gordon,et al.  Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology , 2018, Alzheimer's & dementia.

[25]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[26]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[27]  Pedro Rosa-Neto,et al.  Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.

[28]  M. Mintun,et al.  Association between tau deposition and antecedent amyloid-&bgr; accumulation rates in normal and early symptomatic individuals , 2017, Brain : a journal of neurology.

[29]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[30]  Jorge Sepulcre,et al.  Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline , 2017, Annals of neurology.

[31]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[32]  Prashanthi Vemuri,et al.  Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status , 2017 .

[33]  Brian A. Gordon,et al.  Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. , 2016, JAMA neurology.

[34]  Min Su Kang,et al.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease , 2016, Molecular Psychiatry.

[35]  David T. Jones,et al.  Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. , 2015, JAMA neurology.

[36]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[37]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[38]  C. Jack,et al.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study , 2014, The Lancet Neurology.

[39]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[40]  Clifford R. Jack,et al.  Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration , 2014, Neurology.

[41]  Cindee M. Madison,et al.  Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. , 2013, JAMA neurology.

[42]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[43]  Denise C. Park,et al.  Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. , 2013, JAMA neurology.

[44]  C. Jack,et al.  Brain injury biomarkers are not dependent on β‐amyloid in normal elderly , 2013, Annals of neurology.

[45]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[46]  C. Jack,et al.  An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.

[47]  Dominic Holland,et al.  Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau , 2011, Annals of neurology.

[48]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[49]  L. Kuller,et al.  Amyloid &bgr; Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia , 2018, JAMA neurology.

[50]  C. Jack,et al.  Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 9-19-17 3 4 5 , 2017 .